BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 10742154)

  • 1. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children.
    Krause PR; Klinman DM
    Nat Med; 2000 Apr; 6(4):451-4. PubMed ID: 10742154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for frequent reactivation of the Oka varicella vaccine strain in healthy vaccinees.
    Krause PR
    Arch Virol Suppl; 2001; (17):7-15. PubMed ID: 11339552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile of varicella vaccine: a 10-year review.
    Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
    J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
    Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
    Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
    Goldman GS
    Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of immunity to live attenuated varicella vaccine in healthy adults.
    Ampofo K; Saiman L; LaRussa P; Steinberg S; Annunziato P; Gershon A
    Clin Infect Dis; 2002 Mar; 34(6):774-9. PubMed ID: 11830801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
    Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
    J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of varicella vaccine.
    Takahashi M; Asano Y; Kamiya H; Baba K; Ozaki T; Otsuka T; Yamanishi K
    J Infect Dis; 2008 Mar; 197 Suppl 2():S41-4. PubMed ID: 18419406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine.
    Watson B
    J Infect Dis; 2008 Mar; 197 Suppl 2():S143-6. PubMed ID: 18419388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.
    Breuer J; Schmid DS; Gershon AA
    J Infect Dis; 2008 Mar; 197 Suppl 2():S147-51. PubMed ID: 18419389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine.
    Asano Y; Nagai T; Miyata T; Yazaki T; Ito S; Yamanishi K; Takahashi M
    Pediatrics; 1985 Apr; 75(4):667-71. PubMed ID: 2984636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
    Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
    Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of vaccination on the epidemiology of varicella zoster virus.
    Edmunds WJ; Brisson M
    J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
    Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Varicella vaccination].
    Senterre J
    Rev Med Brux; 2004 Sep; 25(4):A223-6. PubMed ID: 15516045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
    Levin MJ; Gershon AA; Weinberg A; Song LY; Fentin T; Nowak B;
    J Infect Dis; 2006 Jul; 194(2):247-55. PubMed ID: 16779732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
    Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
    J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey.
    Alp H; Altinkaynak S; Ertekin V; Kiliçaslan B; Giiraksin A
    Health Policy; 2005 Apr; 72(1):119-24. PubMed ID: 15760704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation and laboratory markers of the Oka-strain varicella-zoster virus.
    Takahashi M; Hayakawa Y; Shiraki K; Yamanishi K; Asano Y; Ozaki T
    Postgrad Med J; 1985; 61 Suppl 4():37-46. PubMed ID: 3014476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.